Rehospitalization following percutaneous coronary intervention for commercially insured patients with acute coronary syndrome: A retrospective analysis

被引:22
作者
Eric S Meadows
Jay P Bae
Anthony Zagar
Tomoko Sugihara
Krishnan Ramaswamy
Rebecca McCracken
Darell Heiselman
机构
[1] Eli Lilly and Company, Indianapolis, IN
[2] InVentiv Clinical Solutions, LLC, Indianapolis, IN
[3] Daiichi Sankyo Inc., Parsippany, NJ
[4] I3 Statprobe, Minneapolis, MN
[5] Global Health Outcomes, Eli Lilly and Company, Indianapolis
[6] MedMining, Geisinger Health System, Danville
关键词
Percutaneous Coronary Intervention; Clopidogrel; Prasugrel; Revascularization Procedure; Diagnosis Related Group;
D O I
10.1186/1756-0500-5-342
中图分类号
学科分类号
摘要
Background: While prior research has provided important information about readmission rates following percutaneous coronary intervention, reports regarding charges and length of stay for readmission beyond 30days post-discharge for patients in a large cohort are limited. The objective of this study was to characterize the rehospitalization of patients with acute coronary syndrome receiving percutaneous coronary intervention in a U.S. health benefit plan. Methods. This study retrospectively analyzed administrative claims data from a large US managed care plan at index hospitalization, 30-days, and 31-days to 15-months rehospitalization. A valid Diagnosis Related Group code (version 24) associated with a PCI claim (codes 00.66, 36.0X, 929.73, 929.75, 929.78-929.82, 929.84, 929.95/6, and G0290/1) was required to be included in the study. Patients were also required to have an ACS diagnosis on the day of admission or within 30days prior to the index PCI. ACS diagnoses were classified by the International Statistical Classification of Disease 9 (ICD-9-CM) codes 410.xx or 411.11. Patients with a history of transient ischemic attack or stroke were excluded from the study because of the focus only on ACS-PCI patients. A clopidogrel prescription claim was required within 60days after hospitalization. Results: Of the 6,687 ACS-PCI patients included in the study, 5,174 (77.4%) were male, 5,587 (83.6%) were <65years old, 4,821 (72.1%) had hypertension, 5,176 (77.4%) had hyperlipidemia, and 1,777 (26.6%) had diabetes. At index hospitalization drug-eluting stents were the most frequently used: 5,534 (82.8%). Of the 4,384 patients who completed the 15-month follow-up, a total of 1,367 (31.2%) patients were rehospitalized for cardiovascular (CV)-related events, of which 811 (59.3%) were revascularization procedures: 13 (1.0%) for coronary artery bypass graft and 798 (58.4%) for PCI. In general, rehospitalizations associated with revascularization procedures cost more than other CV-related rehospitalizations. Patients rehospitalized for revascularization procedures had the shortest median time from post-index PCI to rehospitalization when compared to the patients who were rehospitalized for other CV-related events. Conclusions: For ACS patients who underwent PCI, revascularization procedures represented a large portion of rehospitalizations. Revascularization procedures appear to be the most frequent, most costly, and earliest cause for rehospitalization after ACS-PCI. © 2012 Meadows et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 20 条
[1]  
Lloyd-Jones D., Adams R., Brown T.M., Carthenon M., Dai S., De Simone G., Ferguson T.B., Ford E., Furie K., Gillespie C., Go A., Greenlund K., Haase N., Hailpern S., Ho P.M., Howard V., Kissela B., Kittner S., Lackland D., Lisabeth L., Marelli A., McDermott M.M., Meigs J., Mozaffarian D., Mussolino M., Nichol G., Roger V.L., Rosamond W., Sacco R., Sorlie P., Heart disease and stroke statistics - 2010 update: A report from the American Heart Association, Circulation, 121, (2010)
[2]  
Turpie A.G., Burden of disease: Medical and economic impact of acute coronary syndromes, Am J Manag Care, 12, (2006)
[3]  
Bosanquet N., Jonsson B., Fox K.A.A., Costs and Cost Effectiveness of Low Molecular Weight Heparins and Platelet Glycoprotein IIb/IIIa Inhibitors: In the Management of Acute Coronary Syndromes, PharmacoEconomics, 21, 16, pp. 1135-1152, (2003)
[4]  
Palmer S., Sculpher M., Phillips Z., Robinson M., Ginnelly L., Bakhai A., Abrams K., Cooper N., Packham C., Alfakih K., Hall A., Gray D., Management of non-ST-elevation acute coronary syndromes: How cost-effective are glycoprotein IIb/IIIa antagonists in the UK National Health Service?, Int J Cardiol, 100, pp. 229-240, (2005)
[5]  
Collinson J., Flather M.D., Fox K.A.A., Findlay I., Rodrigues E., Dooley P., Ludman P., Adgey J., Bowker T.J., Mattu R., Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK), European Heart Journal, 21, 17, pp. 1450-1457, (2000)
[6]  
Heart & Stroke Encyclopedia, (2011)
[7]  
Quality Forum N., Candidate Hospital Care Additional Priorities: 2007 Performance Measure, (2007)
[8]  
For Medicare C., Services M., Application of incentives to reduce avoidable readmissions to hospitals, Fed Regist, 73, pp. 23673-23675, (2008)
[9]  
Menzin J., Wygant G., Hauch O., Jackel J., Friedman M., One-year costs of ischemic heart disease among patients with acute coronary syndromes: Findings from a multi-employer claims database, Current Medical Research and Opinion, 24, 2, pp. 461-468, (2008)
[10]  
Curtis J.P., Schreiner G., Wang Y., Chen J., Spertus J.A., Rumsfeld J.S., Brindis R.G., Krumholz H.M., All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of medicare patients, J Am Coll Cardiol, 54, pp. 903-907, (2009)